Richard H. Stanford, PharmD, MS


COPD Exacerbation Costs in the IMPACT Study: A Within-Trial Analysis

May 06, 2020

Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.

Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT

November 18, 2019

This cost analysis using data from the Study to Understand Mortality and Morbidity in COPD (SUMMIT) trial found that fluticasone furoate/vilanterol reduced the rates and costs of combined chronic obstructive pulmonary disease (COPD) exacerbations and revascularization/cardiovascular events versus placebo.